Study of HEMO-CAR-T therapy in pediatric acute myeloid leukemia and pediatric acute lymphoblastic leukemia
Latest Information Update: 01 Oct 2024
At a glance
- Drugs HEMO-CAR-T cell therapy-Hemogenyx (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
Most Recent Events
- 27 Sep 2024 According to a Hemogenyx Pharmaceuticals media release, company is looking forward for this clinical trials expected to begin shortly at M.D. Anderson Cancer Center in Texas
- 18 Jun 2024 New trial record
- 17 Jun 2024 According to a Hemogenyx Pharmaceuticals media release, company is seeking to expand the HEMO-CAR-T indication to include pediatric acute myeloid leukemia and a subset of pediatric acute lymphoblastic leukemia patients. An amendment to the clinical protocol to include pediatric AML is currently under review by third party experts. If approved, the Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site.